SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-22-026538
Filing Date
2022-05-13
Accepted
2022-05-13 17:01:29
Documents
46
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0322_actinium.htm   iXBRL 10-Q 646805
2 CERTIFICATION f10q0322ex31-1_actinium.htm EX-31.1 10262
3 CERTIFICATION f10q0322ex31-2_actinium.htm EX-31.2 10340
4 CERTIFICATION f10q0322ex32-1_actinium.htm EX-32.1 4084
5 CERTIFICATION f10q0322ex32-2_actinium.htm EX-32.2 4148
  Complete submission text file 0001213900-22-026538.txt   2890770

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE atnm-20220331.xsd EX-101.SCH 31887
7 XBRL CALCULATION FILE atnm-20220331_cal.xml EX-101.CAL 20484
8 XBRL DEFINITION FILE atnm-20220331_def.xml EX-101.DEF 140058
9 XBRL LABEL FILE atnm-20220331_lab.xml EX-101.LAB 287731
10 XBRL PRESENTATION FILE atnm-20220331_pre.xml EX-101.PRE 149593
40 EXTRACTED XBRL INSTANCE DOCUMENT f10q0322_actinium_htm.xml XML 220793
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

IRS No.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36374 | Film No.: 22923765
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences